FS-222 is under clinical development by F-star Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FS-222’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FS-222 overview
FS-222 is under development for the treatment of solid tumor including PD-1 refractory melanoma, ovarian cancer , non-small cell lung cancer (NSCLC), mucosal and cutaneous melanoma, triple negative breast cancer (TNBC), mesothelioma and MSS colorectal cancer. The drug candidate is a mAb-square immuno-regulatory monoclonal antibody. The therapeutic candidate consists of Fcab region in place of normal Fc region. It is a tetravalent Bi-specific monoclonal antibody act by targeting cells expressing CD137 and PD-L1. It is administered through intravenous route. It is being developed based on Fcab platform technology.
F-star Therapeutics overview
F-star Therapeutics, a subsidiary of invoX Pharma Ltd, is a clinical-stage biopharmaceutical company that develops novel, innovative tetravalent bispecific antibodies for cancer and serious illnesses. The company’s pipeline products include FS118, FS120, FS222 and SB 11285. Its pipeline candidates treat rescuing clinical practice improvement (CPI) treatment failures and improving outcomes in the clinical practice improvement (CPI) naive, improving outcomes in programmed cell death ligand 1 (PD-L1) low tumors, improving CPI and chemotherapy outcomes. F-star Therapeutics partners programs include multiple blood-brain barriers, multiple immuno-oncology, STING inhibitors and multiple next-generation bispecific antibodies. The company works in partnership with Denali Therapeutics Inc, Merck KGaA and Takeda Pharmaceutical Company Limited. It operates in the UK and the US. F-star Therapeutics is headquartered in Cambridge, England, the UK.
For a complete picture of FS-222’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
